Depression. Seasonal affective disorder.
Swallow whole. Avoid bedtime dosing. ≥18yrs: Depression: initially 150mg once daily in the AM for at least 3 days; if tolerated, increase to 300mg once daily at least 24 hrs apart. May increase after several weeks to max 450mg once daily. Seasonal affective disorder: start in autumn, taper and stop in early spring. 150mg once daily in AM; if tolerated, increase to 300mg once daily after 1 week. Max 300mg/day. Severe hepatic cirrhosis: max 150mg every other day. Mild-moderate hepatic cirrhosis, or renal impairment: consider reduced dose and/or dose frequency.
<18yrs: not recommended.
Seizure disorders. Bulimia. Anorexia nervosa. Within 14 days of discontinuing MAOIs. Concomitant linezolid or IV methylene blue. Abrupt withdrawal of sedatives or alcohol. Other forms of bupropion (eg, Zyban).
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or changes. History or risk of seizures; discontinue if seizure occurs: do not restart. Hepatic or renal impairment (monitor closely). Bipolar disorder. Psychosis. Unstable heart disease. CHF. Recent MI. Maintain at lowest effective dose. Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Do not start with concomitant linezolid or IV methylene blue; if treatment necessary, discontinue bupropion before starting. Monitor for 2 weeks or until 24 hours after last dose of linezolid or IV methylene blue, whichever comes first. Avoid alcohol. Levodopa, amantadine may increase toxicity. Caution with drugs that lower seizure threshold (eg, quinolones, theophylline, antidiabetics, anorectics, CNS stimulants, systemic steroids, antidepressants, antipsychotics) or factors that lower seizure threshold (eg, opiate or cocaine addiction, excessive use of alcohol or sedatives). Caution with drugs metabolized by CYP2B6 (eg, orphenadrine, cyclophosphamide, thiotepa, ticlopidine, clopidogrel) or CYP2D6 including tricyclic antidepressants, SSRIs (eg, paroxetine, fluoxetine, sertraline), antipsychotics (eg, haloperidol, risperidone, thioridazine), β-blockers (eg, metoprolol), Class 1C antiarrhythmics (eg, propafenone, flecainide); consider dose reduction. May be affected by metabolic enzyme inducers (eg, carbamazepine, phenobarbital, phenytoin), or inhibitors (eg, cimetidine). Monitor for hypertension with nicotine replacement.
CNS stimulation (eg, agitation, insomnia, seizures, tremor, dizziness), mania/hypomania, psychosis, weight change, dry mouth, headache, migraine, nausea, constipation, diarrhea, edema, rash (rarely may be serious, eg, erythema multiforme, Stevens-Johnson syndrome), palpitations, urinary frequency, sweating, tinnitus, myalgia, hypertension.
XL tabs—30, 90; SR tabs—60; Immediate-rel tabs—100